ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS
Clinical trials for ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental leukemia drug made available for patients who have no other options
Disease control AVAILABLEThis program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard …
Matched conditions: ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS
Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Scientists hunt for clues to improve leukemia treatment after transplant
Knowledge-focused Recruiting nowThis study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…
Matched conditions: ACUTE MYELOID LEUKEMIA, WITH KMT2A REARRANGEMENTS
Sponsor: University of Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC